Foghorn Therapeutics Files Routine 8-K, Confirms Nasdaq Listing

Ticker: FHTX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, compliance

TL;DR

**Foghorn Therapeutics filed a routine 8-K, no big news, just standard corporate info.**

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its registration on The Nasdaq Global Market under the trading symbol FHTX. This filing is a routine update, indicating no major new events but rather a confirmation of existing corporate structure and compliance. For investors, this means there are no immediate red flags or significant positive developments reported, suggesting a 'business as usual' status for the company.

Why It Matters

This filing is a standard procedural update, confirming Foghorn Therapeutics' registration and listing details, which is important for maintaining transparency and compliance with SEC regulations.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing with no new material information, thus posing a low risk.

Analyst Insight

A smart investor would view this as a routine, non-event filing. It provides no new material information to warrant a change in investment strategy for Foghorn Therapeutics Inc. (FHTX).

Key Numbers

  • $0.0001 — Par Value per Share (This is the nominal value assigned to each share of common stock by Foghorn Therapeutics Inc.)

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Global Market (company) — the exchange where Foghorn Therapeutics' common stock is registered
  • FHTX (other) — the trading symbol for Foghorn Therapeutics Inc.
  • January 8, 2024 (date) — the date of the earliest event reported and the filing date
  • $0.0001 (dollar_amount) — par value per share of common stock

FAQ

What is the purpose of Foghorn Therapeutics Inc.'s 8-K filing dated January 8, 2024?

The 8-K filing by Foghorn Therapeutics Inc. on January 8, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily serving as a Regulation FD Disclosure and to provide information on Financial Statements and Exhibits. It confirms the company's registration and listing details.

On which stock exchange is Foghorn Therapeutics Inc.'s common stock registered?

Foghorn Therapeutics Inc.'s Common Stock, with a $0.0001 par value per share, is registered on The Nasdaq Global Market.

What is the trading symbol for Foghorn Therapeutics Inc.?

The trading symbol for Foghorn Therapeutics Inc. is FHTX.

What is the earliest event reported date in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024.

What is the business address of Foghorn Therapeutics Inc. as stated in the filing?

The business address of Foghorn Therapeutics Inc. is 500 Technology Square, Suite 700, Cambridge, MA 02139.

Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-08 07:04:40

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Foghorn Therapeutics Inc. (the "Company") issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Additionally, the Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated January 2024, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued on January 8, 2024 99.2 Investor Presentation dated January 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael LaCascia Michael J. LaCascia Chief Legal Officer Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.